Resources

Useful Resources for Psoriasis

New Zealand Resources

The following resources have been compiled to help you get support outside the HUMIRA AbbVie Care programme. We hope you find them useful.

Medsafe Consumer Information

Download Consumer Medicine Information (PDF)

Psoriasis and Psoriatic Arthritis New Zealand Facebook

The Psoriasis and Psoriatic Arthritis NZ Facebook Group is a community for people with Psoriasis and Psoriasis Arthritis. The group welcomes new members to connect, share stories and tips and support one another.

Psoriasis and Psoriatic Arthritis New Zealand Facebook

DermNet New Zealand Trust

DermNet NZ provides authoritative information about skin diseases, conditions and treatment for patients and their health professionals.

dermnetnz.org/topics/psoriasis

Overseas Resources

Please note that treatment available in other countries may not be available in New Zealand.

National Psoriasis Foundation (USA)

Working to find a cure for Psoriasis and Psoriasis Arthritis and to eliminate their devastating effects through research, advocacy and education.

www.psoriasis.org

Talk with your doctor

We’ve put together a checklist that you can take along to your dermatologist visit to discuss symptoms and treatment options.

Download your ‘Getting ready for your dermatologist visit’ guide

Download your guide

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.